1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Verona Pharma plc
  6. Summary
    VRNA   US9250501064

VERONA PHARMA PLC

(VRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
4.440 USD   -0.89%
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/23European ADRs Move Lower in Thursday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
4.42(c) 4.48(c) 4.59(c) 4.48(c) 4.44(c) Last
83 746 29 237 57 662 33 471 17 015 Volume
+9.68% +1.36% +2.46% -2.40% -0.89% Change
More quotes
Estimated financial data (e)
Sales 2022 6,74 M 8,17 M 8,17 M
Net income 2022 -64,8 M -78,5 M -78,5 M
Net cash position 2022 45,6 M 55,3 M 55,3 M
P/E ratio 2022 -5,16x
Yield 2022 -
Sales 2023 9,62 M 11,7 M 11,7 M
Net income 2023 -70,2 M -85,1 M -85,1 M
Net Debt 2023 25,9 M 31,3 M 31,3 M
P/E ratio 2023 -6,13x
Yield 2023 -
Capitalization 221 M 268 M 268 M
EV / Sales 2022 26,0x
EV / Sales 2023 25,7x
Nbr of Employees 25
Free-Float 95,5%
More Financials
Company
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. It is developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company is evaluating nebulized ensifentrine in its Phase III clinical program ENHANCE... 
More about the company
Ratings of Verona Pharma plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about VERONA PHARMA PLC
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/23European ADRs Move Lower in Thursday Trading
MT
06/17Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launc..
MT
06/16European ADRs Fall Sharply in Thursday Trading
MT
06/16TRANSCRIPT : Verona Pharma plc - Special Call
CI
06/15European ADRs Move Higher in Wednesday Trading
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/10European ADRs Tumble in Friday Trading
MT
06/09Verona Pharma Completes Enrollment in Phase 3 Enhance-1 Trial of Potential COPD Drug Ca..
MT
06/09Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine f..
AQ
06/09Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine f..
CI
06/07European ADRs Move Higher in Tuesday Trading
MT
06/06Verona Pharma to Host KOL Event on June 16, 2022
AQ
06/03European ADRs Move Lower in Friday Trading
MT
More news
News in other languages on VERONA PHARMA PLC
06/29Les ADR européens progressent légèrement dans la négociation de mercredi
06/28Les ADR européens en baisse dans les échanges de mardi
06/23Les ADR européens sont en baisse jeudi
06/16Les ADR européens chutent fortement dans la négociation de jeudi
06/15Les ADR européens sont en hausse mercredi
More news
Analyst Recommendations on VERONA PHARMA PLC
More recommendations
Chart VERONA PHARMA PLC
Duration : Period :
Verona Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,44 $
Average target price 19,83 $
Spread / Average Target 347%
EPS Revisions
Managers and Directors
David S. Zaccardelli President, CEO & Executive Director
Mark W. Hahn Chief Financial Officer
David Raymond Ebsworth Non-Executive Chairman
Kathleen Rickard Chief Medical Officer
Tara Rheault Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
VERONA PHARMA PLC-33.33%268
GILEAD SCIENCES, INC.-13.95%78 031
VERTEX PHARMACEUTICALS27.66%70 632
REGENERON PHARMACEUTICALS, INC.-5.37%64 046
WUXI APPTEC CO., LTD.-14.46%44 352
BIONTECH SE-45.76%33 979